ABUS Arbutus Biopharma Corp

MIXED Impact: 4/10 Institutional Cluster
Horizon weeks Processed 1d 6h ago
Institutional cluster: 6 buyers, 3 sellers (mixed)

Executive Summary

A mixed institutional cluster in ABUS for Q3 2024 shows 6 buyers (net +$6.2M) led by Schwab and Citadel doubling their positions, while 3 sellers trimmed $1.5M, including Hudson Bay and Woodline Partners. The buying is dominated by passive/quant funds, reducing signal strength, while the selling comes from active asset managers, suggesting divergent views on Arbutus's near-term prospects.

Key Financial Metrics

Direction
mixed
Buy Value
$6.2M
Sell Value
$1.5M
Net Flow
$4.7M

Institutional Positions

Net institutional flow: $4.7M

▲ Buyers (6)

InstitutionActionChangePosition ValueValue Δ
Schwab DOUBLED +218.5% $4.7M $3.5M
Citadel DOUBLED +319.5% $2.3M $1.9M
Legal & General Group DOUBLED +856.2% $561.0K $514.0K
Group One Trading DOUBLED +127.4% $229.0K $148.0K
Zurcher Kantonalbank DOUBLED +453.1% $144.0K $123.0K
Russell Investments Group ADD +38.1% $18.0K $8.0K

▼ Sellers (3)

InstitutionActionChangePrev ValueValue Δ
Hudson Bay Capital Management TRIM -38.9% $5.2M -$1.2M
Woodline Partners TRIM -27.9% $2.9M -$290.6K
National Bank Of Canada TRIM -37.1% $8.0K -$1.9K

Actionable Insight

The mixed cluster with passive buying and active selling creates no clear directional signal. Monitor next quarter's 13F for follow-through — if active managers resume buying, it would strengthen the bullish case. The stock's 89% analyst bullish rating contrasts with the cautious institutional selling, warranting a wait-and-see approach.

Key Facts

  • 6 institutional buyers added $6.2M in new holdings, led by Schwab (+$3.5M) and Citadel (+$1.9M)
  • 3 institutional sellers trimmed $1.5M, led by Hudson Bay Capital Management (-$1.2M) and Woodline Partners (-$291K)
  • Net institutional flow was +$4.7M into ABUS during Q3 2024
  • Buying dominated by passive/quant funds (Schwab, Citadel) — weaker signal than active manager accumulation
  • Selling by active managers (Woodline, Hudson Bay) suggests some informed profit-taking or risk reduction

Financial Impact

Net institutional inflow of approximately $4.7M into ABUS during Q3 2024, with total buying of $6.2M versus selling of $1.5M

institutional ownershipfloat

Risk Factors

  • 13F data is 45+ days stale — positions may have been unwound since quarter-end
  • Passive/quant buying may reflect index rebalancing rather than fundamental conviction
  • Active manager selling (Woodline, Hudson Bay) could indicate thesis deterioration not yet reflected in analyst ratings

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-ABUS-2024-Q3
5 reports for ABUS
Performance horizon
100% Hit rate 4 of 4 directional calls best @ T+1▲ +4.46%Apr 15, 2026
Filters
Rows
Reports for ABUS — sortable, filterable
Type Now
Jun 12, 2026
1d ago
Institutional Cluster
MIXED ★ 4/10
$4.28 awaiting T+5awaiting T+5
May 13, 2026
4w ago
8-K
BULLISH ★ 7/10
$4.31 $4.20▼ −2.55%▼ −1.39%
May 13, 2026
4w ago
Press Release
BULLISH ★ 8/10
$4.31 $4.20▼ −2.55%▼ −1.39%
Apr 15, 2026
8w ago
8-K
BULLISH ★ 7/10
$4.48 $4.43▼ −1.12%▼ −2.76%
Mar 23, 2026
11w ago
Press Release
BULLISH ★ 9/10
$4.42 $4.30▼ −2.71%▲ +0.85%
Showing 5 of 5

US Market Status

Market Closed — Opens Mon (47h 34m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access